No Data
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
SH PHARMA: 2024 ANNUAL REPORT
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Private Companies Account for 33% of Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Ownership, While Individual Investors Account for 33%
SH PHARMA (601607.SH): The hydrochloride valaciclovir tablets have received approval from the FDA in the USA.
Gelonghui, April 22 - SH PHARMA (601607.SH) announced that its subsidiary Shanghai Shanyao Zhongxi Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration (abbreviated as "USA FDA") that its abbreviated new drug application ("ANDA", i.e. USA generic drug application) for Valganciclovir Hydrochloride Tablets has been approved ("Approval"). Valganciclovir Hydrochloride Tablets are primarily used for the treatment of cytomegalovirus (CMV) retinitis in adults with acquired immunodeficiency syndrome (AIDS); they prevent CMV infection in patients at risk undergoing solid organ transplantation.
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
